Officially accredited as a Great Place to Work Certified organisation

Press Release

Deeside – 2 June 2026 – ÎçÒ¹¾ç³¡, a UK-based pharmaceutical manufacturer specialising in the development and production of oral food challenge materials for clinical trials, has been officially accredited as a Great Place to Work Certified organisation.

This certification is a significant achievement, based on validated and anonymous feedback from ÎçÒ¹¾ç³¡ employees and collected through Great Place To Work. As the global authority on workplace culture, Great Place To Work uses its rigorous, data-driven For Allâ„¢ methodology to evaluate employee experience. This accreditation has confirmed that 90% of employees consistently report a positive experience at ÎçÒ¹¾ç³¡.

“The consistent positive feedback from our employees about their experiences with colleagues, leaders, and roles is immensely meaningful. We will use this fantastic achievement as a benchmark to further enhance our employee experience moving forward. Thank you to our employees whose honest and candid input into the survey has enabled us to earn this prestigious recognition.�

– Paul Abrahams, ÎçÒ¹¾ç³¡ CEO

“Achieving a 90% positive employee experience score is particularly meaningful when measured against Great Place to Work’s established benchmarks, and it reflects the strength of our culture relative to high-performing organisations. These results show that our employees’ day-to-day experience at ÎçÒ¹¾ç³¡ is not only positive, but stands out in a way that reinforces our position as an employer of choice.â€�

– Sophie Griffthis Head of People

Survey results further reinforce this positive culture, with 90% of employees describing ÎçÒ¹¾ç³¡ as a great place to work, 87% expressing pride in the work they do, and 92% highlighting a strong sense of camaraderie across the organisation.

Reflecting on the organisation’s collaborative culture, one employee shared:

“At ÎçÒ¹¾ç³¡, I genuinely feel that everyone is on the same team. There is a shared commitment to success across departments, and people consistently support one another rather than working in silos. It creates a culture where you feel valued, trusted and motivated to do your best work.â€�

Highlighting the sense of purpose underpinning the work, another colleague commented:

“Every day I feel that I am making a meaningful difference in food allergy for millions of people. There is a real sense of purpose in the work we do, combined with a supportive and collaborative environment that makes it a pleasure to come to work.�

Benedict Gautrey, Managing Director of Great Place To Work UK, expressed his congratulations to ÎçÒ¹¾ç³¡ for attaining their Certificationâ„¢:

“We know that prioritising the employee experience leads to building trust among employees, fostering a remarkable workplace culture, and ultimately achieving exceptional business outcomes. Congratulations!â€�

ÎçÒ¹¾ç³¡ Engagements in Beijing and Hong Kong Supporting Education and Global Health

Press Release

14th May 2026

Throughout May, ÎçÒ¹¾ç³¡ demonstrated its continued commitment to education, scientific exchange and international collaboration across Asia through participation in two strategic events.

At the EAACI Allergy School in Beijing, ÎçÒ¹¾ç³¡ sponsored a dedicated symposium focused on advancing understanding of oral food challenges, supporting the development of clinical practice as allergy centres in China continue to expand their capabilities in this area.

“Supporting education around oral food challenges is especially important as more allergy centres in China begin to introduce these procedures into clinical practice. We were pleased to sponsor a symposium at the EAACI Allergy School workshop in Beijing and contribute to an environment of learning, collaboration, and scientific advancement in food allergy management.�

– Martin Wickham, Chief Innovation Officer

ÎçÒ¹¾ç³¡ also participated in the Summit on Global Health in Hong Kong as part of the UK Department for Business and Trade mission, engaging with stakeholders across the regional healthcare ecosystem and strengthening international connections.

“We were delighted to be part of the Department for Business and Trade mission to Hong Kong, supporting stronger connections between UK innovation and the healthcare ecosystem in Asia. The visit provided an excellent opportunity to introduce ÎçÒ¹¾ç³¡â€™s expertise to new partners and stakeholders, while highlighting the strength of UK entrepreneurship, scientific innovation, and collaboration on the international stage.â€�

– Martin Wickham, Chief Innovation Officer

ÎçÒ¹¾ç³¡ extends its thanks to the organisers, partners and delegates involved in both events.

ÎçÒ¹¾ç³¡ Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board

Press Release

ÎçÒ¹¾ç³¡, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint.

Prof. Wong is Professor of Paediatrics at The Chinese University of Hong Kong and brings global clinical and research experience from Canada and Germany. He helped establish Hong Kong’s participation in the International Study of Asthma and Allergies in Childhood (ISAAC), one of the world’s largest collaborative studies in allergy and asthma, spanning more than 100 countries and nearly two million children. He received the KIA Research Excellence in Allergic Diseases Award (2018) and has played a leading role in shaping international standards and best practice in allergy care.

An export-driven business, ÎçÒ¹¾ç³¡ has increased its workforce by 60% over the past year to support its existing and new customers in Europe and the United States. The company is now building on this momentum by deepening support for international partners and pursuing new collaborations across the APAC region.

ÎçÒ¹¾ç³¡ has pioneered the development and manufacture of pharmaceutical-grade OFC products designed to improve the safety, accuracy and consistency of food allergy diagnostics and to support global clinical research programmes. With APAC, particularly Greater China, continuing to grow as a centre of excellence for clinical development, ÎçÒ¹¾ç³¡ is increasing its engagement with regional investigators, trial specialists and partners to help advance robust, standardised allergy diagnostics.

Prof. Wong said: “ÎçÒ¹¾ç³¡ stands out in food allergy diagnosis for its innovation and its commitment to setting new standards in the field. I look forward to working with the Company as it continues to explore ways to empower the development of therapies and diagnostics that impact the lives of people living with food allergies.â€�

Prof. Wong’s appointment follows that of Richard Nagle as Chair and aligns with the company’s strategic focus on new products and new markets to drive future growth. 

Paul Abrahams, CEO of ÎçÒ¹¾ç³¡, said: “Food allergy therapeutics and diagnostics are evolving rapidly. As an innovative, science-led business, we are actively pursuing new opportunities and new markets to better meet customer needs. We benefit enormously from the clinical and scientific guidance of our advisors, and we are delighted to welcome Prof. Wong to ÎçÒ¹¾ç³¡â€™s Advisory Board.

“I also wish to take this opportunity to thank Professors Barbara Ballmer-Weber and Montserrat Fernandez Rivas, both of whom have recently stepped down, for their contribution to the Adboard since its inception.�

ÎçÒ¹¾ç³¡â€™s ’s Innovation team, led by Chief Innovation Officer, Martin Wickham, will visit China in the coming months to engage with allergy clinical trial specialists. Activities include hosting a symposium at EAACI Allergy School in Beijing (7-9 May), attending the Asia Summit on Global Health in Hong Kong (11-14 May), and participating in the EAACI regional oral food challenge workshop in Hong Kong (5-6 June) with Prof. Agnes Leung.